Рак лёгких

Рак лёгких прячется от иммунитета: учёные нашли клетки, способные распознавать опасную опухоль

Рак лёгких прячется от иммунитета: учёные нашли клетки, способные распознавать опасную опухоль Правда.Ру

Blood test offers new way to track lung cancer

Northwestern Medicine scientists and collaborators have demonstrated a novel liquid biopsy technique that can measure cancer burden and reveal molecular characteristics of small cell lung cancer (SCLC), according to a new study published in the Journal of Clinical Investigation.

How Can Clinicians Stay Ahead of Immunotherapy Resistance in Lung Cancer?

CEACAM5 May Become a New Targetable Biomarker in Lung Cancer

Lung Cancer Awareness Month Tipsheet; Resources for Smoking Cessation, Early Screening — and New Research and Treatments Against Deadly Disease | Newswise

Lung Cancer Awareness Month Tipsheet; Resources for Smoking Cessation, Early Screening — and New Research and Treatments Against Deadly Disease | Newswise Newswise

Urvashi Prasad: India Accounts for Just 1.41% of Global Lung Cancer Clinical Trials Over 20 Years

Urvashi Prasad: India Accounts for Just 1.41% of Global Lung Cancer Clinical Trials Over 20 Years Oncodaily

Adding Imdelltra to Maintenance Treatment Impacts Survival in Advanced Small Cell Lung Cancer

Adding Imdelltra to Maintenance Treatment Impacts Survival in Advanced Small Cell Lung Cancer news.cancerconnect.com

Osimertinib regimen extends survival for EGFR-mutant NSCLC

Osimertinib plus savolitinib reduced the risk for progression or death by 45% compared with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer, according to randomized phase 3 trial data. The findings, presented at European Society for Medical Oncology Congress, also…

4 Lung Cancer Results From ESMO 2026 Patients Should Know

4 Lung Cancer Results From ESMO 2026 Patients Should Know Cure Today

Savolitinib Plus Tagrisso Added About Five Months of Median Survival Over Chemo in MET-Driven Lung Cancer

Savolitinib Plus Tagrisso Added About Five Months of Median Survival Over Chemo in MET-Driven Lung Cancer Medical Daily

ALK versus ROS1 lung cancer: Differences in testing and treatment

ALK versus ROS1 lung cancer: Differences in testing and treatment Mayo Clinic Press

Targeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer

Targeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer MedPage Today

4th Cologne Conference on Lung Cancer (CCLC) 2027

4th Cologne Conference on Lung Cancer (CCLC) 2027 Oncodaily

Overcoming Barriers in the Treatment of Limited-Stage Small Cell Lung Cancer With a Focus on Low- and Middle-Income Countries: A Narrative Review

Overcoming Barriers in the Treatment of Limited-Stage Small Cell Lung Cancer With a Focus on Low- and Middle-Income Countries: A Narrative Review Cureus

EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer

EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer The Clinical Trial Vanguard